Trial Profile
A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms COBRA
- 26 Apr 2023 Planned primary completion date changed from 24 Dec 2022 to 24 Dec 2024.
- 07 Jun 2021 Planned End Date changed from 24 Dec 2023 to 24 Dec 2024.
- 07 Jun 2021 Planned primary completion date changed from 24 Dec 2021 to 24 Dec 2022.